Kventiax

Quetiapine, the active ingredient in Kventiax, is an atypical antipsychotic presented as an oral tablet for oral use. It is used to treat schizophrenia, bipolar disorder and as adjunct therapy for major depressive disorder in adults.

GNH USA supplies Kventiax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches and reliable logistics for global markets. The company adheres to EU GMP standards and provides full documentation for regulatory review. Customers benefit from competitive pricing and dedicated technical support throughout the procurement process.

Quetiapine acts on dopamine and serotonin pathways to manage several psychiatric conditions.

- Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. - Bipolar disorder (manic episodes): stabilizes mood and decreases mania severity. - Bipolar disorder (depressive episodes): alleviates depressive symptoms. - Major depressive disorder (adjunct therapy): enhances response when added to antidepressants.

Quetiapine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness - Dizziness - Dry mouth - Constipation - Weight gain

Serious or Rare Side Effects: - Agranulocytosis - Neuroleptic malignant syndrome - Tardive dyskinesia - Suicidal thoughts or behaviors - Severe hypotension

When prescribing quetiapine, clinicians should observe several safety considerations.

- Monitor blood pressure: watch for orthostatic hypotension especially at treatment initiation. - Assess metabolic parameters: track weight, glucose and lipid levels regularly. - Evaluate for suicidal ideation: particularly in younger adults and during dose changes. - Use caution in hepatic impairment: dose adjustment may be required. - Adjust dosing in elderly: increased sensitivity to sedation and falls. - Store at room temperature: keep in original container, protect from moisture and light.

Quetiapine interacts with several drug classes that may alter its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase quetiapine plasma levels. - Strong CYP3A4 inducers (e.g., rifampin): may reduce quetiapine exposure. - CNS depressants (alcohol, benzodiazepines): additive sedation and respiratory depression. - Antihypertensive agents: enhanced hypotensive effect. - QT‑prolonging drugs (e.g., sotalol): increased risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Other antipsychotics: cumulative dopamine blockade. - Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome. - Antihistamines: increased sedation. - Anticholinergic agents: may worsen cognitive effects. - Carbamazepine: moderate CYP3A4 induction reducing quetiapine levels.